article · PubMed
A six-year retrospective review at the Lagos University Teaching Hospital examined the clinical records of eighty-three children referred for micropenis between March 2018 and March 2024. Clinical evaluation of stretched penile length revealed that sixteen children fell within normal reference ranges, avoiding unnecessary testing. The remaining sixty-seven confirmed cases accounted for over twelve per cent of all new paediatric endocrine consultations during the period, with the majority occurring in peripubertal boys. Documented co-morbidities included obesity, Down syndrome, sickle cell anaemia, and growth hormone deficiency. Substantial barriers to standard clinical management were identified. Due to financial constraints, more than two-thirds of the patients could not undergo any diagnostic investigations, and only about thirty-one per cent completed human chorionic gonadotrophin stimulation testing. Treatment was further impeded by a lack of available age-appropriate testosterone formulations.
Micropenis can signal underlying endocrine conditions or disorders of sex development that require timely medical care. The findings highlight serious diagnostic and therapeutic bottlenecks in tertiary healthcare, including financial barriers to routine testing and a lack of paediatric drug formulations, which delay proper intervention for affected children.
The findings point to an unmet clinical demand for affordable diagnostic testing and the formal licensing and supply of age-appropriate testosterone formulations for paediatric patients. Pharmaceutical manufacturers, diagnostic providers, and public health programmes are the primary relevant actors, with the evidence demonstrating immediate real-world treatment gaps rather than early-stage product concepts.
AI-generated from the published abstract. Always read the original work before citing.
Background: Micropenis in a child may not only be related to cosmesis but raise the suspicion of a disorder of sex development or endocrine conditions requiring urgent attention. The study aims to describe the clinical and laboratory profile of children referred for micropenis over a six-year period at the Lagos University Teaching Hospital (LUTH) and highlight challenges encountered in management of these children. Methodology: This was a retrospective study. Case records of patients who were referred with complaints or diagnoses of "micropenis" from March 2018 to March 2024 were analysed. The Health Research and Ethics Committee of LUTH approved the study. Results: Eighty-three children were referred for micropenis. On review, the stretched penile length (SPL) in 16 children (mean [SD]age of 8.9± 3.42 years) was within reference ranges and they were excluded from further evaluations. The remaining 67 children with confirmed micropenis constituted 12.4% of 541 new paediatric endocrine cases. The median age (range) at presentation was 9(0.7-16) years. Boys within the peripubertal age group constituted the majority of the patients. Co-morbidities included obesity, Down Syndrome, sickle cell anaemia, and growth hormone deficiency. Challenges in management included unaffordability of laboratory tests as only 21 children (31.3%) performed the human chorionic gonadotrophin (hCG) stimulation, our local testing, more than half (68.6%) could not carry out any investigations and age-appropriate/ preparations of testosterone were unavailable for treatment. Conclusion: Micropenis constituted a sizeable proportion of the paediatric endocrine consultations in our setting. Accurate measurements are important to exclude unaffected children and prevent unnecessary expensive investigations. The National Health Insurance Services (NHIS) should be strengthened to enable patients to access necessary investigations and treatment related to micropenis. Licensing of age-appropriate drugs for treatment by relevant authorities is advocated.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.71480/nmj.v66i2.819
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
